[1] KOROMPILIAS AV, BERIS AE, LYKISSAS MG, et al.Femoral head osteonecrosis: why choose free vascularized fibula grafting. Microsurgery.2011;31:223-228.
[2] OHZONO K, TAKAOKA K, SAITO S, et al.Intraosseous arterial architecture in nontraumatic avascular necrosis of the femoral head: microangiographic and histologic study.Clin Orthop Relat Res. 1992; 277:79-88.
[3] KIM HK.Pathophysiology and new strategies for the treatment of Legg-Calvé-Perthes disease. J Bone Joint Surg Am. 2012; 94:659-669.
[4] KIM HK, SU PH. Development of flattening and apparent fragmentation following ischemic necrosis of the capital femoral epiphysis in a piglet model.J Bone Joint Surg Am. 2002;84:1329-1334.
[5] RODAN GA, RESZKA AA.Bisphosphonate mechanism of action. Curr Mol Med.2002;2:571-577.
[6] RESZKA AA, RODAN GA.Bisphosphonate mechanism of action. Curr Rheumatol Rep.2003;5:65-74.
[7] MATHOV I, PLOTKIN LI, SGARLATA CL, et al.Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro.J Bone Miner Res.2001;16:2050-2056.
[8] JAKOBSEN T, BAAS J, BECHTOLD JE, et al.The effect of soaking allograft in bisphosphonate: A pilot dose response study.Clin Orthop Relat Res.2010;468:867874.
[9] 谢小伟,谭振,裴福兴,等.二磷酸盐在防治股骨头坏死中的研究现状[J].中国矫形外科杂志,2013,21(9):893-896.
[10] SHARMA D, IVANOVSKI S, SLEVIN M, et al. Bisphosphonate-related osteonecrosis of jaw (BRONJ): diagnostic criteria and possible pathogenic mechanisms of an unexpected anti-angiogenic side effect.Vasc Cell.2013;5(1):1.
[11] VANDERMEER JS, KAMIYA N, AYA AY J, et al.Local administration of ibandronate and bone morphogenetic protein 2 after ischemic osteonecrosis of the immature femoral head: A combined therapy that stimulates bone formation and decreases femoral head deformity.J Bone Joint Surg Am. 2011;93:905-913.
[12] FLEISCH H, BISAZ S.Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol.1962;203:671-675.
[13] ROELOFS AJ, THOMPSON K, EBETINO FH, et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes andmacrophages. Curr Pharm Des. 2010;16(27):2950-2960.
[14] RESZKA AA, RODAN GA.Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 2003;1(2):45-52.
[15] SHINODA H, ADAMEK G, FELIX R, et al.Structure-activity relationships of various bisphosphonates.Calcif Tissue Int. 1983;35(1):87-99.
[16] EBETINO FH, FRANCIS MD, ROGERS MJ, et al. Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharmacother.1998;9:233-243.
[17] THOMPSON K, ROGERS MJ, COXON FP, et al.Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.Mol Pharmacol. 2006;69:1624-1632.
[18] MURAKAMI H, TAKAHASHI N, SASAKI T, et al.A possible mechanism of the specific action of bisphosphonates on osteoclasts: Tiludronate preferentially affects polarized osteoclasts having ruffled borders.Bone.1995;17:137-144.
[19] HIROI-FURUYA E, KAMEDA T, HIURA K, et al.Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts.Calcif Tissue Int.1999;64:219-223.
[20] COXON FP, ROGERS MJ.The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int.2003;72:80-84.
[21] FRITH JC, MÖNKKÖNEN J, AURIOLA S,et al.The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.Arthritis Rheum.2001;44:2201-2210.
[22] LEHENKARI PP, KELLINSALMI M, NÄPÄNKANGAS JP, et al. Further insight into the mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adeninecontaining metabolite.Mol Pharmacol. 2002;62:1255-1262.
[23] VAN BEEK ER, LÖWIK CWGM, PAPAPOULOS SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.Bone. 2002;30: 64-70.
[24] D'AMELIO P, GRIMALDI A, DI BELLA S, et al.Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.J Bone Miner Res. 2008;23:373-379.
[25] D'AMELIO P, GRIMALDI A, CRISTOFARO MA, et al. Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int. 2010;21:1741-1750.
[26] PLOTKIN LI, WEINSTEIN RS, PARFITT AM, et al.Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.J Clin Invest.1999;104:1363-1374.
[27] FOLLET H, LI J, PHIPPS RJ, et al.Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.Bone.2007;40:1172-1177.
[28] PLOTKIN LI, MANOLAGAS SC, BELLIDO T.Transduction of cell survival signals by connexin-43 hemichannels.J Biol Chem. 2002;277:8648-8657.
[29] PLOTKIN LI, LEZCANO V, THOSTENSON J, et al.Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo.J Bone Miner Res.2008; 23:1712-1721.
[30] REINHOLZ GG, GETZ B, PEDERSON L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60:6001-6007.
[31] DUQUE G, RIVAS D.Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells.J Bone Miner Res.2007;10:1603-1611.
[32] VIERECK V, EMONS G, LAUCK V, et al.Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.Biochem Biophys Res Commun.2002; 291: 680-686.
[33] PAN B, FARRUGIA AN, TO LB, et al.The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE) J.Bone Miner Res. 2004;19:147-154.
[34] IDRIS AI, ROJAS J, GREIG IR, et al.Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.Calcif Tissue Int.2008;82:191-201.
[35] ORRISS IR, KEY ML, COLSTON KW, et al.Inhibition of osteoblast function in vitro by aminobisphosphonates.J Cell Biochem. 2009;106:109-118.
[36] BELLIDO T, PLOTKIN LI.Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability. Bone. 2011;49:50-55.
[37] BOULENC X, MARTI E, JOYEUX H, et al.Importance of the paracellular pathway for the transport of new bisphosphonate using the human CACO-2 monolayers model.Biochem Pharmacol. 1993;46:1591-1600.
[38] KASTING GB, FRANCIS MD.Retention of etidronate in human, dog, and rat.J Bone Miner Res. 1992;7:513-522.
[39] 商红,张石革,孙定人.双膦酸盐类药物的研究进展与临床合理应用[J].中国药房,2003,14(4):245-247.
[40] ASSOULINE-DAYAN Y, CHANG C, GREENSPAN A, et al. Pathogenesis and natural history of osteonecrosis.Semin Arthritis Rheum. 2002;32:94-124.
[41] BOSS JH, MISSELEVICH I.Osteonecrosis of the femoral head of laboratory animals: the lessons learned from a comparative study of osteonecrosis in man and experimental animals.Vet Pathol.2003;40:345-354.
[42] KIM HK, KIM JH, ABBAS AA, et al.Alendronate enhances osteogenic differentiation of bone marrow stromal cells: A preliminary study.Clin Orthop Relat Res.2009;467:3121-3128.
[43] GOU W, WANG X, PENG J, et al.Controlled delivery of zoledronate improved bone formation locally in vivo.PLoS One.2014;9:e91317.
[44] LAI KA, SHEN WJ, YANG CY, et al.The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.J Bone Joint Surg Am.2005;87(10):2155-2159.
[45] NISHII T, SUGANO N, MIKI H, et al.Does alendronate prevent collapse in osteonecrosis of the femoral head? Clin Orthop Relat Res.2006;443:273-279.
[46] AGARWALA S, JAIN D ,JOSHI VR, et al.Efficacy of alendronate, a bisphosphonate,in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford). 2005;44(3):352-359.
[47] AGARWALA S, SULE A, PAI BU, et al.Alendronate in the treatment of avascular necrosis of the hip.Rheumatology (Oxford). 2002;41(3):346-347.
[48] AGARWALA S, SHAH SB.Ten-year follow-up of avascular necrosis of femoral head treated with alendronate for 3 years.J Arthroplasty.2011;26(7):1128-1134.
[49] LUO RB, LIN T, ZHONG HM, et al.Evidence for using alendronate to treat adult avascular necrosis of the femoral head: a systematic review.Med Sci Monit.2014;20:2439-2447.
[50] CHEN CH, CHANG JK, LAI KA, et al.Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis: a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study.Arthritis Rheum. 2012;64(5):1572-1578.
[51] LEE YK, HA YC, CHO YJ, et al.Does Zoledronate Prevent Femoral Head Collapse from Osteonecrosis? A Prospective, Randomized, Open-Label, Multicenter Study.J Bone Joint Surg Am.2015;97(14):1142-1148.
[52] YUAN HF, GUO CA, YAN ZQ.The use of bisphosphonate in the treatment of osteonecrosis of the femoral head: a meta-analysis of randomized control trials.Osteoporos Int. 2016;27(1):295-299.
[53] GIANAKOS AL, MOYA-ANGELER J, DUGGAL S, et al.The Efficacy of Bisphosphonates with Core Decompression and Mesenchymal Stem Cells Compared with Bisphosphonates Alone in the Treatment of Osteonecrosis of the Hip: a Retrospective Study.HSS J.2016;12:137-144.
[54] KANG P, PEI F, SHEN B, et al.Are the results of multiple drilling and alendronate for osteonecrosis of the femoral head better than those of multiple drilling? A pilot study. Joint Bone Spine. 2012;79:67-72.
[55] WANG CJ, WANG FS, YANG KD, et al.Treatment of osteonecrosis of the hip: comparison of extracorporeal shockwave with shockwave and alendronate. Arch Orthop Trauma Surg. 2008;128(9):901-908.
[56] MA J,SUN W,GAO F,et al.Porous Tantalum Implant in Treating Osteonecrosis of the Femoral Head: Still a Viable Option? Sci Rep.2016;6:28227.
[57] MA JH, GUO WS, LI ZR, et al.Local Administration of Bisphosphonate-soaked Hydroxyapatite for the Treatment of Osteonecrosis of the Femoral Head in Rabbit. Chin Med J (Engl).2016;129(21): 2559-2566.
[58] KIM HK, ARUWAJOYE O, DU J, et al.Local administration of bone morphogenetic protein-2 and bisphosphonate during non-weight-bearing treatment of ischemic osteonecrosis of the femoral head: an experimental investigation in immature pigs.J Bone Joint Surg Am.2014; 96(18):1515-1524.
[59] CHENG TL, MURPHY CM, CANTRILL LC, et al.Local delivery of recombinant human bone morphogenetic proteins and bisphosphonate via sucrose acetate isobutyrate can prevent femoral head collapse in Legg-Calve-Perthes disease: a pilot study in pigs.Int Orthop.2014;38(7):1527-1533.
[60] AYAAY J, ATHAVALE S, MORGAN BAGLEY S, et al. Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head.J Bone Miner Res. 2007;22:93-100.
[61] KIM HK, SANDERS M, ATHAVALE S, et al.Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head.Bone. 2006;39:205-212.
[62] SØRENSEN M, BARCKMAN J, BECHTOLD JE, et al. Preclinical evaluation of zoledronate to maintain bone allograft and improve implant fixation in revision joint replacement. J Bone Joint Surg Am.2013;95:1862-1868.
|